J&J’s Nipocalimab Data Signals the FcRn Gold Rush Has a Real Leader
J&J's nipocalimab cut SLE disease activity in Phase 2 JASMINE—and with Phase 3 already recruiting, FcRn blockade is becoming...
FcRn inhibitors
argenx’s $1.3 Billion Quarter Proves FcRn Dominance — Now the Real Test Begins
argenx hit $1.3B in Q1 2026 product sales, up 63% YoY. With two VYVGART label expansions pending and empasiprubart...